Pharming Group Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Fabrice Chouraqui

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Fabrice Chouraqui

no data

Görev süresi

Mr. Fabrice Chouraqui, Ph D., has been Chief Executive Officer and Executive Director of Pharming Group N.V. since March 4, 2025. He has been the Chief Executive Officer-Partner of Flagship Pioneering and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sijmen de Vries	Advisor	no data	US$2.81m	2.13% € 11.6m
Fabrice Chouraqui	CEO & Executive Director	no data	Veri yok	0.68% € 3.7m
Jeroen Wakkerman	Chief Financial Officer	4.3yrs	Veri yok	0.063% € 346.0k
Mireille Sanders	Chief Operations Officer	5.6yrs	Veri yok	0.12% € 641.6k
Susanne Embleton	Investor Relations Manager	no data	Veri yok	Veri yok
Ruud Van Outersterp	Chief Ethics & Compliance Officer	3.8yrs	Veri yok	0.024% € 132.6k
Ines Bernal	Chief People Officer	less than a year	Veri yok	Veri yok
Anurag Relan	Chief Medical Officer	3.8yrs	Veri yok	0.027% € 147.9k
Stephen Toor	Chief Commercial Officer & GM Americas	8.2yrs	Veri yok	0.028% € 150.7k
Alexander Breidenbach	Chief Business Officer	1.5yrs	Veri yok	0.0096% € 52.5k
Bruno M. Giannetti	Consultant	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 0QCO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fabrice Chouraqui	CEO & Executive Director	no data	Veri yok	0.68% € 3.7m
Leonard Kruimer	Independent Non-Executive Director	3.8yrs	US$90.00k	0.018% € 97.3k
Mark Pykett	Independent Non-Executive Director	4.3yrs	US$87.00k	0.021% € 117.3k
Deborah Jorn	Independent Non-Executive Vice-Chairperson	5.8yrs	US$87.00k	0.024% € 129.8k
Steven Baert	Independent Non-Executive Director	3.8yrs	US$90.00k	0.018% € 97.3k
Barbara Yanni	Independent Non-Executive Director	4.3yrs	US$94.00k	0.021% € 117.3k
Richard Peters	Non-Executive Chairman of Board	1.5yrs	US$46.00k	0.0092% € 50.5k
Jabine van der Meijs	Independent Non-Executive Director	3.8yrs	US$94.00k	0.018% € 97.3k

3.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0QCO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/03/19 05:09
Gün Sonu Hisse Fiyatı	2025/03/19 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Pharming Group N.V. 14 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Savin	Edison Investment Research
Simon Scholes	First Berlin Equity Research GmbH
Joseph Pantginis	H.C. Wainwright & Co.

Pharming Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Pharming Group N.V. Announces CEO Changes

Insufficient new directors

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Recent updates

Pharming Group N.V., Annual General Meeting, Jun 11, 2025

Full year 2024 earnings released: US$0.016 loss per share (vs US$0.016 loss in FY 2023)

Pharming Group N.V. to Report Q2, 2025 Results on Jul 31, 2025

Pharming Group N.V. Announces CEO Changes

Pharming Group N.V. to Report Q4, 2024 Results on Mar 13, 2025

Pharming Group N.V. Announces Positive Topline Data in Pediatric Clinical Trial of Leniolisib

Third quarter 2024 earnings released: US$0.002 loss per share (vs US$0.005 profit in 3Q 2023)

Pharming Group Announces Start of Phase II Clinical Trial of Leniolisib for Primary Immunodeficiencies (PIDs) with Immune Dysregulation

Second quarter 2024 earnings released: US$0.002 loss per share (vs US$0.002 profit in 2Q 2023)

Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union

Insufficient new directors

Pharming Group N.V. Provides Revenue Guidance for 2024

First quarter 2024 earnings released: US$0.019 loss per share (vs US$0.019 loss in 1Q 2023)

Pharming Group N.V. announced that it expects to receive €100 million in funding

Full year 2023 earnings released: US$0.015 loss per share (vs US$0.021 profit in FY 2022)

Pharming Group N.V. to Report Q2, 2024 Results on Aug 01, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: US$0.005 (vs US$0.014 in 3Q 2022)

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

First half 2023 earnings released: US$0.017 loss per share (vs US$0.03 profit in 1H 2022)

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Now 20% undervalued

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 26%

Full year 2022 earnings released: EPS: US$0.021 (vs US$0.025 in FY 2021)

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Now 20% undervalued

Now 22% undervalued

Investor sentiment improved over the past week

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

High number of new directors

Investor sentiment improved over the past week

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Third quarter 2022 earnings released: EPS: US$0.014 (vs US$0 in 3Q 2021)

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.009 in 2Q 2021)

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

First quarter 2022 earnings released: EPS: US$0.005 (vs US$0.013 in 1Q 2021)

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

High number of new directors

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Second quarter 2021 earnings released: EPS €0.008 (vs €0.016 in 2Q 2020)

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Independent Non-Executive Director has left the company

Independent Non-Executive Director has left the company

First quarter 2021 earnings released: EPS €0.011 (vs €0.013 in 1Q 2020)

Full year 2020 earnings released: EPS €0.052 (vs €0.058 in FY 2019)

Executive Director & CEO recently bought €489k worth of stock

Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021

Full year 2020 earnings released: EPS €0.051 (vs €0.058 in FY 2019)

Revenue beats expectations

Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week